Skip to main content
Market Activity
CLOSE
Market Activity
Stocks
Funds + ETFs
Indexes
Commodities
Cryptocurrency
Currencies
Futures
Fixed Income
Global Markets
Quick Links
Real-Time Quotes
After-Hours Quotes
Pre-Market Quotes
Nasdaq-100
Symbol Screener
Online Brokers
Glossary
Sustainable Bond Network
Symbol Change History
IPO Performance
Ownership Search
Dividend History
Market Events
Economic Calendar
Earnings
IPO Calendar
Dividend Calendar
SPO Calendar
Analyst Activity
Analyst Recommendations
Daily Earnings Surprise
Forecast Changes
Commodities
Gold
Copper
Crude Oil
Natural Gas
Nasdaq Data
Statistical Milestones
Total Returns
Daily Market Statistics
Most Active
See All Market Activity
News + Insights
CLOSE
Markets
Companies
Coronavirus
Technology
Personal Finance
Financial Advisors
Topics
Blockchain
Commodities
Cryptocurrencies
Earnings
Governance
IPOs
Retirement
Stocks
Features
World Reimagined
Smart Investing
Innovation Realized
Coronavirus Watch Newsletter
Cultural Capital
Market Makers by Phil Mackintosh
TotalMarkets Podcast
TradeTalks
Nasdaq Watch
See All News + Insights
Solutions
CLOSE
Raise & Access Capital
List with Nasdaq
Nasdaq Private Market Solutions
Investor Relations Intelligence
Optimize Governance Practices
Nasdaq Boardvantage Board Portal Software
Board Evaluations
Nasdaq Center for Board Excellence
ESG Reporting/Data Management
Corporate Services COVID-19 Center
Transform with Technology
Market Infrastructure Technology
Non-Traditional Exchanges & New Markets
Sell-Side Technology
Buy-Side Technology
Catastrophe Risk Technology
Gain Market Intelligence
Buy-Side Intelligence
Investment Data & Analytics
Market Data & Feeds
Nasdaq Global Indexes
Institutional Capital with eVestment
Trade Global Markets
Equities
Equity Derivatives
ETFs & ETPs
Fixed Income
Commodities
Connectivity
Post Trade Services
Clearing
Exchange Oversight
Sustainable Bonds
See All Solutions
About
CLOSE
Our People
Careers
Press Center
Contact
Quick Links
Diversity, Inclusion and Belonging
Nasdaq Marketsite
Investor Relations
ESG Reporting Guide
European Markets
Nasdaq Nordic Foundation
Nasdaq Thought Leadership
Nasdaq Initiatives
Nasdaq Responds to Covid-19
TotalMarkets
Public Policy Advocacy
Sustainability at Nasdaq
Nasdaq Entrepreneurial Center
Nasdaq Ventures
Nasdaq and the Cloud
See All About
Log in
Data is currently not available
Data is currently not available
Find a Symbol
Search for Press Releases
When autocomplete results are available use up and down arrows to review and enter to select. Touch device users, explore by touch or with swipe gestures.
Edit my quotes
Viela Bio, Inc. Common Stock
(VIE)
Nasdaq
Listed
Nasdaq
100
Data is currently not available
Add to Watchlist
Add to Portfolio
Quotes
Summary
Live
Real-Time
Live
After-Hours
Live
Pre-Market
Live
Charts
Live
NEWS & ANALYSIS
News
Live
Press Releases
Live
Analyst Research
Live
Dividend History
Historical Quotes
Historical NOCP
Financials
Earnings
P/E & PEG Ratios
Option Chain
Short Interest
Institutional Holdings
Insider Activity
SEC Filings
Revenue EPS
VIE
VIE PRESS RELEASES
VIE Press Releases
Published
Nov 10, 2020
Viela Bio Reports Third Quarter 2020 Financial Results and Program Highlights
Published
Nov 10, 2020
Published
Nov 5, 2020
Viela Bio Announces Final Results from Phase 1b Trial of VIB7734 in Patients with Cutaneous Lupus Erythematosus
Published
Nov 5, 2020
Published
Nov 2, 2020
Viela Bio to Webcast Third Quarter 2020 Financial Results and Program Highlights on November 10, 2020
Published
Nov 2, 2020
Published
Sep 3, 2020
Viela Bio Announces Data Presentations at the 8th Joint ACTRIMS-ECTRIMS Meeting, MS Virtual 2020
Published
Sep 3, 2020
Published
Aug 12, 2020
Viela Bio Reports Second Quarter 2020 Financial Results and Program Highlights
Published
Aug 12, 2020
Published
Aug 5, 2020
Viela Bio to Webcast Second Quarter 2020 Financial Results and Program Highlights on August 12, 2020
Published
Aug 5, 2020
Published
Jun 11, 2020
Viela Bio Announces U.S. FDA Approval of UPLIZNA™ (inebilizumab-cdon) for the Treatment of Neuromyelitis Optica Spectrum Disorder (NMOSD)
Published
Jun 11, 2020
Published
May 27, 2020
Viela Bio Announces Pricing of Public Offering of Common Stock
Published
May 27, 2020
Published
May 26, 2020
Viela Bio Announces Proposed Public Offering of Common Stock
Published
May 26, 2020
Published
May 13, 2020
Viela Bio Reports First Quarter 2020 Financial Results and Program Highlights
Published
May 13, 2020
Published
May 13, 2020
Viela Bio Announces Positive Interim Results from a Phase 1b Study of VIB7734 in Patients with Cutaneous Lupus Erythematosus
Published
May 13, 2020
Published
May 6, 2020
Viela Bio to Webcast First Quarter 2020 Financial Results and Program Highlights on May 13, 2020
Published
May 6, 2020
Published
Apr 30, 2020
Viela Bio Announces Election of Rachelle Jacques to its Board of Directors
Published
Apr 30, 2020
Published
Mar 25, 2020
Viela Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Business Highlights
Published
Mar 25, 2020
Published
Mar 18, 2020
Viela Bio to Webcast Fourth Quarter and Full Year 2019 Operating and Financial Results on March 25, 2020
Published
Mar 18, 2020
Published
Dec 11, 2019
Viela Bio Announces Initiation of Phase 2b Trial of VIB4920 in Sjögren’s Syndrome
Published
Dec 11, 2019
Published
Nov 14, 2019
Viela Bio Reports Third Quarter 2019 Financial Results and Business Highlights
Published
Nov 14, 2019
Published
Oct 9, 2019
Viela Bio Enters Strategic Collaboration with Mitsubishi Tanabe Pharma to Develop and Commercialize Inebilizumab for Autoimmune Diseases in Japan and Other Asia Regions
Published
Oct 9, 2019
Published
Oct 7, 2019
Viela Bio Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Published
Oct 7, 2019
Published
Oct 2, 2019
Viela Bio Announces Pricing of Initial Public Offering
Published
Oct 2, 2019
...
Back to VIE Overview
Related Symbols
AMZN
Data is currently not available
AAPL
Data is currently not available
TSLA
Data is currently not available
INTC
Data is currently not available
My Quotes
My Quotes
Watchlist
Portfolio
Add/Edit Symbols
View as Table
Add symbols
now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing
stocks
,
funds and ETFs
, and
more asset classes.
/
Add to Watchlist
Edit Watchlist
Your Watchlist is empty.
Add a Symbol
Create your Watchlist to save your favorite quotes on Nasdaq.com.
Log in
or
create a free account
to get started.
/
Outsmart the market with Smart Portfolio analytical tools powered by TipRanks.
Go to Smart Portfolio
Back
Add a symbol to your watchlist
Most Active
Data is currently not available
Edit My Quotes
Add up to 25 symbols
Enter up to 25 symbols separated by spaces. These symbols will be available throughout the site during your session.
Save data
Data is currently not available
Your symbols have been updated
You'll now be able to see real-time price and activity for your symbols on the My Quotes of Nasdaq.com.
Continue